Developer docs
API playgroundTry for free, no card

Search company profiles

Sientra

Full company profile

uuid00053tr

Namestring
Sientra
Legal namestring
Tiger Aesthetics Medical, LLC
Websiteurl
sientra.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Sientra is a US-based medical aesthetics company that designs, manufactures, and sells FDA-approved silicone gel breast implants and breast tissue expanders for augmentation and reconstruction procedures. Founded around 2003 and commercially launched in 2012 following FDA approval, the company is operated by Tiger Aesthetics Medical, LLC, headquartered in Conshohocken, Pennsylvania, and trades publicly on NASDAQ under ticker SIEN. The company employs 101-250 people and has accumulated over 600,000 implants in real-world use over 13+ years.

The core product line features proprietary Gel-Shell Integration technology and High-Strength Cohesive (HSC/HSC+) gel across more than 200 implant options in 6 profile levels. Supporting products include the AlloX2 dual-port tissue expander with integrated drain and the Dermaspan soft-shell tissue expander. Sientra markets the industry's only 20-year warranty (Platinum20), covering rupture, capsular contracture, BIA-ALCL, double capsule, and late forming seroma — a differentiator against competitors Mentor, Allergan, and Motiva. Post-market surveillance data shows rupture rates of 0.44% and capsular contracture III/IV rates of 1.09%.

Sientra operates an enterprise field sales motion, selling exclusively through board-certified plastic surgeons in the United States. The company uses a surgeon-locator tool on its website, participates in industry conferences, and maintains a direct sales force targeting surgeon partnerships. Patients cannot purchase directly — they must be referred to a participating board-certified surgeon. Marketing leverages Instagram, LinkedIn, RealSelf (where Sientra holds a 97% Worth It rating as of March 2025), before/after galleries, and patient education resources. Revenue is generated through hardware sales of implants and tissue expanders to surgical providers. The company has raised over $400M across multiple funding rounds between 2007 and 2022, including a $13.2M public offering in October 2022, and has incurred persistent operating losses throughout its public history.

Short descriptiontext

Sientra is a US medical aesthetics company that designs, manufactures, and sells FDA-approved silicone gel breast implants and tissue expanders exclusively through board-certified plastic surgeons for breast augmentation and reconstruction, with over 600,000 implants placed since 2012.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFranklin, United States
HQ citystring
Franklin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast implants, silicone gel implants, tissue expanders, aesthetic surgery devices, breast reconstruction devices
Industry1 code
13D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
CodeHLAHAEAJPrimaryYes
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Breast Implants and Medical Aesthetic Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Silicone Breast Implants
TypeHardware Sales
Description

Sale of FDA-approved silicone gel breast implants for breast augmentation and reconstruction. Products are sold exclusively through board-certified plastic surgeons. Revenue is generated through direct sales to surgical providers.

globenewswire.com
2Breast Tissue Expanders
TypeHardware Sales
Description

Sale of breast tissue expanders including AlloX2 and Dermaspan products for breast reconstruction. These temporary expanders are used prior to permanent implant placement.

sientra.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sientra is a medical aesthetics company that develops, manufactures, and sells FDA-approved silicone gel breast implants and breast tissue expanders used in breast augmentation and breast reconstruction procedures. Its products are sold exclusively to and through board-certified plastic surgeons in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Rupture rate of 0.44% based on post-market surveillance data from 2012-2025 with over 600,000 implants
+5 more records
Product overview1 text field

Sientra is a medical aesthetics company offering a focused portfolio of FDA-approved breast implants and tissue expanders. The core product line consists of Sientra Silicone Gel Breast Implants with proprietary High-Strength Cohesive (HSC/HSC+) gel technology featuring gel-shell integration, available in over 200 options across 6 profile levels. Supporting the implant business are two tissue expanders: AlloX2 (with integrated drain technology) and Dermaspan (soft-shell design). The company differentiates through its Platinum 20 warranty program—the only 20-year warranty in the industry—and emphasizes safety data with over 600,000 implants in real-world use since 2012.

Product and service4 records
1Sientra Silicone Gel Breast Implants
CategoryBreast Implants
Description

FDA-approved silicone gel breast implants available in multiple shapes, profiles, projections, and surface textures, used by board-certified plastic surgeons for breast augmentation and revision surgery.

2AlloX2 Breast Tissue Expander
CategoryTissue Expanders
Description

Breast tissue expander used in two-stage breast reconstruction procedures to gradually stretch the tissue pocket before placement of a permanent breast implant.

3Dermaspan Breast Tissue Expander
CategoryTissue Expanders
Description

Smooth-surface breast tissue expander used in two-stage breast reconstruction to create the tissue pocket for subsequent permanent implant placement.

4OPERA Post-Market Surveillance Study
CategoryClinical Surveillance
Description

Long-term post-market clinical study collecting safety and effectiveness data on Sientra silicone gel breast implants in real-world use.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Charitable partnership supporting Reshaping Lives: Full Circle program that provides no-cost breast reconstructive surgery for post-mastectomy women living in poverty in the United States. Sientra participates as a product donor supporting the initiative.

Strategic tierCoreTypeOthers
Description

Tiger Aesthetics Medical, LLC is the parent company and manufacturer of Sientra breast implants. The company is headquartered in Conshohocken, PA and operates under the Tiger Aesthetics brand.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Mentor (Johnson & Johnson MedTech)
TypeDirect peer
Description

Mentor is the US market leader in breast implants (MemoryGel, MemoryShape) and a direct competitor to Sientra with a similar surgeon-channel sales model and FDA-approved silicone gel portfolio.

TypeDirect peer
Description

Allergan's Natrelle line is one of the largest silicone and saline breast implant brands globally, sold through plastic surgeons with comparable warranty programs, directly competing with Sientra in the US channel.

TypeDirect peer
Description

Establishment Labs manufactures Motiva breast implants with SmoothSilk/SilkSurface technologies and is expanding in the US. Comparable cohesive gel and surface technology positioning make it a direct peer to Sientra.

TypeDirect peer
Description

GC Aesthetics is an established global breast implant manufacturer (Eurosilicone, Nagor, PERLE). Comparable silicone gel and shaped implant portfolio serving plastic surgeons internationally.

TypeDirect peer
Description

Polytech manufactures silicone gel breast implants (MESMO, Replicon) and tissue expanders (CPX4) primarily outside the US, with similar surgeon-channel GTM and a comparable product mix including expanders.

TypeEmerging player
Description

Ideal Implant developed a structured saline breast implant sold through board-certified plastic surgeons in the US. Smaller scale but overlapping customer base and surgeon distribution channel.

TypeRegional player
Description

Sebbin is a French manufacturer of silicone gel breast implants and expanders primarily serving European and select international markets. Comparable product line with limited direct US overlap but directly comparable implants.

TypeBroad incumbent
Description

While broader than breast implants, Allergan/AbbVie's aesthetics franchise provides context on a large incumbent operating in the same plastic surgeon channel that Sientra depends on.

9Tissue Expander Adjacent – Stryker
TypeBroad incumbent
Description

Stryker's medical division manufactures surgical implants and reconstruction-related devices, providing a broader incumbent benchmark for the reconstructive surgery segment where Sientra's expanders compete.

TypeOthers
Description

RealSelf is the patient review and surgeon-discovery platform that drives Sientra's consumer demand engine (97% Worth It rating). It is a key channel partner rather than a competitor, included as an ecosystem enabler.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sientra

Breast Implants and Medical Aesthetic Devicessientra.com

Sientra is a US medical aesthetics company that designs, manufactures, and sells FDA-approved silicone gel breast implants and tissue expanders exclusively through board-certified plastic surgeons for breast augmentation and reconstruction, with over 600,000 implants placed since 2012.

What Sientra does

Sientra is a US-based medical aesthetics company that designs, manufactures, and sells FDA-approved silicone gel breast implants and breast tissue expanders for augmentation and reconstruction procedures. Founded around 2003 and commercially launched in 2012 following FDA approval, the company is operated by Tiger Aesthetics Medical, LLC, headquartered in Conshohocken, Pennsylvania, and trades publicly on NASDAQ under ticker SIEN. The company employs 101-250 people and has accumulated over 600,000 implants in real-world use over 13+ years.

The core product line features proprietary Gel-Shell Integration technology and High-Strength Cohesive (HSC/HSC+) gel across more than 200 implant options in 6 profile levels. Supporting products include the AlloX2 dual-port tissue expander with integrated drain and the Dermaspan soft-shell tissue expander. Sientra markets the industry's only 20-year warranty (Platinum20), covering rupture, capsular contracture, BIA-ALCL, double capsule, and late forming seroma — a differentiator against competitors Mentor, Allergan, and Motiva. Post-market surveillance data shows rupture rates of 0.44% and capsular contracture III/IV rates of 1.09%.

Sientra operates an enterprise field sales motion, selling exclusively through board-certified plastic surgeons in the United States. The company uses a surgeon-locator tool on its website, participates in industry conferences, and maintains a direct sales force targeting surgeon partnerships. Patients cannot purchase directly — they must be referred to a participating board-certified surgeon. Marketing leverages Instagram, LinkedIn, RealSelf (where Sientra holds a 97% Worth It rating as of March 2025), before/after galleries, and patient education resources. Revenue is generated through hardware sales of implants and tissue expanders to surgical providers. The company has raised over $400M across multiple funding rounds between 2007 and 2022, including a $13.2M public offering in October 2022, and has incurred persistent operating losses throughout its public history.

Sientra firmographics

Firmographics
Name
Sientra
Legal name
Tiger Aesthetics Medical, LLC
Website
https://sientra.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Sientra is a US medical aesthetics company that designs, manufactures, and sells FDA-approved silicone gel breast implants and tissue expanders exclusively through board-certified plastic surgeons for breast augmentation and reconstruction, with over 600,000 implants placed since 2012.
Ownership category
akta.pro rank

Sientra industry classification

Industry
Product category
Breast Implants and Medical Aesthetic Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)

Keywords

  • Breast implants
  • Silicone gel implants
  • Tissue expanders
  • Aesthetic surgery devices
  • Breast reconstruction devices

Where Sientra is headquartered

Location

Headquarters

HQ city
Franklin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sientra business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Silicone Breast Implants: Sale of FDA-approved silicone gel breast implants for breast augmentation and reconstruction. Products are sold exclusively through board-certified plastic surgeons. Revenue is generated through direct sales to surgical providers.
  2. Breast Tissue Expanders: Sale of breast tissue expanders including AlloX2 and Dermaspan products for breast reconstruction. These temporary expanders are used prior to permanent implant placement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Sientra product offering

Product offering

Core offering

Sientra is a medical aesthetics company that develops, manufactures, and sells FDA-approved silicone gel breast implants and breast tissue expanders used in breast augmentation and breast reconstruction procedures. Its products are sold exclusively to and through board-certified plastic surgeons in the United States.

Product overview

Sientra is a medical aesthetics company offering a focused portfolio of FDA-approved breast implants and tissue expanders. The core product line consists of Sientra Silicone Gel Breast Implants with proprietary High-Strength Cohesive (HSC/HSC+) gel technology featuring gel-shell integration, available in over 200 options across 6 profile levels. Supporting the implant business are two tissue expanders: AlloX2 (with integrated drain technology) and Dermaspan (soft-shell design). The company differentiates through its Platinum 20 warranty program—the only 20-year warranty in the industry—and emphasizes safety data with over 600,000 implants in real-world use since 2012.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sientra Silicone Gel Breast Implants FDA-approved silicone gel breast implants available in multiple shapes, profiles, projections, and surface textures, used by board-certified plastic surgeons for breast augmentation and revision surgery.
  • AlloX2 Breast Tissue Expander Breast tissue expander used in two-stage breast reconstruction procedures to gradually stretch the tissue pocket before placement of a permanent breast implant.
  • Dermaspan Breast Tissue Expander Smooth-surface breast tissue expander used in two-stage breast reconstruction to create the tissue pocket for subsequent permanent implant placement.
  • OPERA Post-Market Surveillance Study Long-term post-market clinical study collecting safety and effectiveness data on Sientra silicone gel breast implants in real-world use.

Quantifiable outcome

  • Rupture rate of 0.44% based on post-market surveillance data from 2012-2025 with over 600,000 implants
  • +5 more outcomes

Companies that use Sientra

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Sientra technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Sientra partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Reshaping Lives AmericaminorStrategic or Co-development PartnerCharitable partnership supporting Reshaping Lives: Full Circle program that provides no-cost breast reconstructive surgery for post-mastectomy women living in poverty in the United States. Sientra participates as a product donor supporting the initiative.
  • Tiger Aesthetics Medical, LLCcoreOthersTiger Aesthetics Medical, LLC is the parent company and manufacturer of Sientra breast implants. The company is headquartered in Conshohocken, PA and operates under the Tiger Aesthetics brand.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Sientra competitors and assessment

Company assessment

Direct peers

  • Mentor (Johnson & Johnson MedTech): Mentor is the US market leader in breast implants (MemoryGel, MemoryShape) and a direct competitor to Sientra with a similar surgeon-channel sales model and FDA-approved silicone gel portfolio.
  • Allergan Aesthetics (AbbVie) – Natrelle: Allergan's Natrelle line is one of the largest silicone and saline breast implant brands globally, sold through plastic surgeons with comparable warranty programs, directly competing with Sientra in the US channel.
  • Establishment Labs (Motiva): Establishment Labs manufactures Motiva breast implants with SmoothSilk/SilkSurface technologies and is expanding in the US. Comparable cohesive gel and surface technology positioning make it a direct peer to Sientra.
  • GC Aesthetics: GC Aesthetics is an established global breast implant manufacturer (Eurosilicone, Nagor, PERLE). Comparable silicone gel and shaped implant portfolio serving plastic surgeons internationally.
  • Polytech Health & Aesthetics: Polytech manufactures silicone gel breast implants (MESMO, Replicon) and tissue expanders (CPX4) primarily outside the US, with similar surgeon-channel GTM and a comparable product mix including expanders.

Emerging players

  • Ideal Implant: Ideal Implant developed a structured saline breast implant sold through board-certified plastic surgeons in the US. Smaller scale but overlapping customer base and surgeon distribution channel.

Regional players

  • Sebbin: Sebbin is a French manufacturer of silicone gel breast implants and expanders primarily serving European and select international markets. Comparable product line with limited direct US overlap but directly comparable implants.

Broad incumbents

  • Allergan (AbbVie) – LATISSE / SkinMedica aesthetics portfolio: While broader than breast implants, Allergan/AbbVie's aesthetics franchise provides context on a large incumbent operating in the same plastic surgeon channel that Sientra depends on.
  • Tissue Expander Adjacent – Stryker: Stryker's medical division manufactures surgical implants and reconstruction-related devices, providing a broader incumbent benchmark for the reconstructive surgery segment where Sientra's expanders compete.

Others

  • RealSelf: RealSelf is the patient review and surgeon-discovery platform that drives Sientra's consumer demand engine (97% Worth It rating). It is a key channel partner rather than a competitor, included as an ecosystem enabler.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Sientra social profiles

Digital presence

Sientra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sientra leadership team

Management profile

Number of profiles

Profiles11 records

Sientra funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sientra M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sientra

What does Sientra do?

Sientra is a medical aesthetics company that develops, manufactures, and sells FDA-approved silicone gel breast implants and breast tissue expanders used in breast augmentation and breast reconstruction procedures. Its products are sold exclusively to and through board-certified plastic surgeons in the United States.

Is Sientra a public or private company?

Sientra is a public company. It is classified as public and is currently operating.

When was Sientra founded?

Sientra was founded in 2012. It employs 101 to 250 people.

Where is Sientra based?

Sientra is headquartered in Franklin, United States, in the North America region.

How does Sientra make money?

Two revenue lines are on record. Silicone Breast Implants are the primary driver. The others are breast Tissue Expanders.

Who are Sientra's main competitors?

Direct peers on record are Mentor (Johnson & Johnson MedTech), Allergan Aesthetics (AbbVie) – Natrelle, Establishment Labs (Motiva), GC Aesthetics and Polytech Health & Aesthetics. Ideal Implant is listed as an emerging player. Sebbin is listed as a regional player. Broad incumbents are Allergan (AbbVie) – LATISSE / SkinMedica aesthetics portfolio and Tissue Expander Adjacent – Stryker. RealSelf is listed as an others.

Does Sientra have an API?

No public API is recorded for Sientra.

What industry is Sientra in?

Sientra's product category is Breast Implants and Medical Aesthetic Devices. Its primary akta.pro industry code is HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireThe Seidel Agency Launches Connection Engineering to Help Brands Get Discovered by AI — and Trusted by PeopleThe Seidel Agency launched Connection Engineering, a service combining AI discoverability, media visibility, and human connection to help brands stand out in search and build trust. It introduces an AI Visibility Score out of 100 and cites Clutch Coffee Bar's growth to 20 locations before a $20 million acquisition by Dutch Bros.openPR.comFuture Perspective: Key Trends Shaping the Scar Massage Silicone Market Until 2030The Business Research Company published a market report projecting the scar massage silicone market to reach $1.99 billion by 2030 with a 9.8% compound annual growth rate, driven by increased homecare treatments, e-commerce accessibility, and demand for non-invasive scar solutions. In April 2024, Nuance Intermediary, LLC acquired the Biocorneum brand from Sientra, Inc. for approximately $8 million as part of Nuance's strategy to expand its portfolio of silicone scar-care products. Additionally, Skinuva launched its Skinuva Scar+ SPF scar defense cream in January 2023, combining traditional scar treatment with broad-spectrum UV protection.PR NewswireScar Treatment Market to Reach US$ 49.2 Bn by 2033 Expands Amid Rising Aesthetic Demand and Technological Innovation - Persistence Market ResearchThe global scar treatment market is projected to grow from approximately US$ 23.0 billion in 2026 to US$ 49.2 billion by 2033, representing a compound annual growth rate of 11.5%, driven by rising aesthetic awareness, advances in minimally invasive therapies, and stronger healthcare infrastructure. In October 2025, Sientra's BIOCORNEUM brand expanded its scar and skin recovery portfolio with a new proprietary bruise care system and an extended range of scar treatment products, positioning itself as a comprehensive recovery-care brand within the medical aesthetics market. Topical products currently dominate the market with a 64.3% share, while laser-based treatments represent the fastest-growing segment, with North America holding the largest regional share at 40.5%.FortunebusinessinsightsU.S. Breast Implants Market Size, ShareThe U.S. breast implants market was valued at USD 1.08 billion in 2022 and is projected to grow at a CAGR of 7.4% through 2030, driven by rising breast augmentation procedures, increasing mastectomy rates due to breast cancer, and new product launches. Key industry players including GC Aesthetics, AbbVie Inc., Johnson & Johnson Services Inc., and Sientra, Inc. are focusing on product innovation and strategic collaborations to expand their market share. In October 2021, the U.S. FDA updated safety requirements for breast implants, restricting sales and distribution to ensure patients consider potential risks, which may act as a restraining factor on market growth.TechnavioCosmetic Surgery and Procedure Devices Market Analysis, Growth & Forecast 2024–2029Technavio has published a 241-page market research report forecasting the global cosmetic surgery and procedure devices market to grow by USD 261.1 billion at a CAGR of 22.3% between 2024 and 2029. The analysis highlights key drivers such as increasing consumer demand for minimally invasive procedures and technological advancements, while noting high treatment costs as a primary challenge. The report provides detailed segmentation data across regions, product types, and end-users, including specific insights into major players like AbbVie Inc. and Sientra Inc.YahooCosmetic Surgery Market Forecast Report and Company Analysis 2025-2033 Featuring AbbVie, Cutera, Sientra, Bausch Health, Johnson & Johnson, Apyx Medical, Hologic, Merz Pharma, Galderma, CynosureResearchAndMarkets.com released a market report projecting the global cosmetic surgery market to grow from US$76.89 billion in 2024 to US$181 billion by 2033, representing a compound annual growth rate of 9.98%. Key growth drivers include technological advancements in non-invasive procedures like Botox and dermal fillers, social media influence promoting aesthetic enhancement, rising disposable incomes in emerging markets, and an aging global population seeking anti-aging treatments. North America is expected to hold the largest market share, with Brazil performing over 1.5 million procedures annually, while challenges include social stigma, ethical concerns about beauty standards, and potential health risks from surgical complications.Business Wire BlogMedical Aesthetics Market Insights 2024-2029 Featuring AbbVie, Bausch Health Companies, Candela, Cutera, Cynosure, Galderma, J&J, Lumenis, Merz Pharma, Sientra, Sinclair, and Sisram Medical - ResearchResearchAndMarkets.com published a market research report on the global Medical Aesthetics Market, valued at USD 21.03 billion in 2023 and projected to reach USD 39.87 billion by 2029, growing at a CAGR of 11.25%. The report covers 48 vendors and identifies the market as highly competitive with prominent international players including AbbVie, Johnson & Johnson, and Galderma driving innovation through strategic collaborations and acquisitions. The Asia-Pacific region is forecast to witness the highest growth rate, driven by expanding patient populations, rising elderly demographics seeking cosmetic enhancements, and increased acceptance of aesthetic procedures among middle and higher-income segments.GlobeNewswireDelisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Atlantic Coastal Acquisition Corp.; Charge Enterprises, Inc.; SagNasdaq announced delisting of common stock for multiple companies, including NanoString Technologies, Remark Holdings, Sunworks, Cyanotech, Sientra, and others. Each company's securities were suspended in February or March 2024 and had not traded on Nasdaq since.Market Research ReportsNorth America Cosmetic Surgery Market Size, Report 2031The North America cosmetic surgery market was valued at US$ 16.2 billion in 2022 and is projected to grow at a CAGR of 6.8%, reaching more than US$ 29.2 billion by 2031. Key drivers include increasing societal acceptance of cosmetic procedures, evolving beauty standards influenced by social media, and growing demand for non-invasive procedures. In May 2023, Apyx Medical secured FDA 510(k) clearance for its Renuvion APR Handpiece for use following liposuction procedures, and Sientra received FDA clearance for its Portfinder technology for subcutaneous port location in tissue expanders.BenzingaWhy Is Surgical Aesthetics Company Sientra Stock Nosediving Today?Sientra Inc withdrew its FY23 guidance and reported interim Q3 revenues of $19.2-19.7 million, significantly below the year-ago figure of $22.6 million and consensus of $24.25 million. The company cited market softness and seasonal headwinds reducing augmentation and reconstruction cases in July and August as key drivers of the underperformance. Sientra also reported declining cash reserves of $14.7-15.2 million as of September 30, 2023, down from $26.1 million at year-end 2022, and announced it is exploring strategic alternatives to improve its balance sheet.